Abbott Labs entering glucose monitoring market with $876 mil. MediSense purchase.
This article was originally published in The Tan Sheet
Executive Summary
ABBOTT ACQUIRING GLUCOSE MONITOR SYSTEMS MAKER MEDISENSE for $876 mil., the firm announced March 29. The definitive agreement, expected to be completed within the next five weeks, would give Abbott entry to the blood glucose monitor market with Waltham, Mass.-based MediSense's line of biosensor-based blood glucose systems, enabling patients with diabetes to test themselves.